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Signiﬁcant neutralizing activity of human immunoglobulin
preparations against pandemic 2009 H1N1
The inﬂuenza-like illness that began in the Unites States and
Mexico was ﬁrst reported by the World Health Organization
(WHO) on 24 April, 2009, and declared a phase 6 pandemic
on 11 June. As of 6 July 2009, over 90 000 cases and more than
400 deaths in some 120 countries had been conﬁrmed (WHO,
2009). Importantly, on July 8th, the WHO announced that
oseltamivir (Tamiﬂu)-resistant viruses had been identiﬁed in
Denmark, Japan and Hong Kong (WHO, 2009).
The pandemic virus 2009 H1N1 was a triple reassortant of
human-, swine- and avian-derived inﬂuenza A virus segments
and the HA gene was classiﬁed as being of swine-origin (Novel
Swine-Origin Inﬂuenza A (H1N1) Virus Investigation Team,
(2009). Evidence is accumulating that speciﬁc IgG antibodies
against this virus are present in certain populations, especially
the elderly (Itoh et al, 2009). However, Katz et al (2009)
reported that cross reactive IgG against a pandemic inﬂuenza
virus (A/California/04/2009) was found in no serum specimens
of children aged 6 months–9 years old, 8% of samples from
5- to 9-year olds, 9% of samples from 18- to 64-year olds, 6%
of samples of 18- to 40-year olds and 33% of samples of those
over 60 years old, suggesting that immunoglobulin prepa-
rations derived from pooled plasma from over 10 000 healthy
donors could contain such cross reactive IgG. The present
study evaluated haemagglutinin-inhibition (HI) and virus
neutralization (VN) activities against 2009 H1N1 and seasonal
H1N1 as a positive control in intravenous human immuno-
globulin (IVIG) preparations manufactured in 1999 and 2008.
An inﬂuenza A/H1N1 vaccine strain (A/New Caledonia/20/
99), a clinical isolate of A/H1N1 (A/Osaka/16/2008), a
classical swine isolate of A/H1N1 (A/Swine/Hokkaido/2/
1981) and a pandemic inﬂuenza isolate of A/H1N1 (A/
Osaka/168/2009 H1N1 pdm) were used in this study. Three
lots (Lot. A, B and C) of IVIG derived from pooled plasma
collected in Japan and manufactured in 2008 (IVIG2008JP,
‘Kenketsu Venoglobulin
 -IH Yoshitomi; Benesis Corp.,
Osaka, Japan’) were also used. In addition, two lots of IVIG
that were manufactured in 1999, derived from plasma pooled
collected in Japan and the USA (IVIG1999JP ‘Kenketsu
Venoglobulin
 -IH’, IVIG1999US ‘Venoglobulin
 -IH; Yoshi-
tomi Pharmaceutical Industries, Ltd. at the time, currently
Benesis Corp.’), were used.
The viruses were propagated in Madin-Darby canine kidney
(MDCK) cells or in the allantoic cavity of chicken embryo-
nated eggs. The culture media and the allantoic ﬂuids
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focus-forming units (FFU) per ml, was titrated in MDCK cells
using peroxidase and an anti-peroxidase (PAP) staining
technique (Okuno et al, 1990). The haemagglutinin-inhibition
(HI) test using 0Æ75% guinea pig red blood cells was carried
out as described previously (Okuno et al, 1993). The results
were expressed as the reciprocal of the highest dilution of the
culture medium to show inhibition. The virus neutralization
(VN) test was carried out as described (Okuno et al, 1990).
Brieﬂy, IVIG was diluted twofold with serum-free medium.
The diluted IVIG (50 ll) was mixed with 100 FFU (50 ll) of
virus, then applied to MDCK cells in a 96-well microplate.
After culturing, the cells were ﬁxed with ethanol and stained by
PAP as above. The results were expressed as the reciprocal of
the dilution giving 50% neutralization.
Intravenous human immunoglobulins were manufactured
using plasma pooled from over 10 000 healthy donors. The
HI and VN activities of IVIGs were titrated against pandemic,
seasonal human and swine inﬂuenza A viruses (Table I). Of
note, both the 1999 and 2008 IVIGs were shown to have
anti pandemic and classical swine inﬂuenza A/H1N1 virus
titres with HI (·4–·8) and VN (·32–·64). The 2008 IVIGs
showed titres against the vaccine strain A/New Caledonia/20/
99, which was isolated in 1999, with HI (·160–·320) and VN
(·640–·1280), while the 1999 IVIGs showed titres with HI
(·10–·40) and VN (·32–·128). These results suggested that
the IVIG derived from the pooled plasma contained a certain
amount of functional IgG, including IgG against pandemic or
classical swine inﬂuenza A/H1N1. Of note, such IgG titres
were slightly higher in the IVIG2008JP products compared
with IVIG1999JP. However, the titres were slightly higher in
IVIG1999US than in IVIG1999JP. Higher titres against the
vaccine and clinical strains were observed in IVIG1999US
than IVIG1999JP. Interestingly, the difference in the increase
in titres against the vaccine strain was much greater between
the products manufactured in 2008 and 1999 than between
the others. This difference seems to be an outcome of
vaccination. Our preliminary results showed a HI titre >·40
in 1Æ2% (7/580), ·20 in 3Æ1% (18/580) and ·10 in 4Æ3% (25/
580), indicating the possible production of hyperimmune
globulin with these sources of plasma collected in 2008,
Japan.
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Table I. Cross reactivity of several lots of IVIG against pandemic 2009, classical swine and seasonal H1N1 viruses.
IVIG
Pandemic 2009
H1N1
A/Osaka/168/
2009(H1N1pdm)
Classical swine
H1N1
A/Swine/
Hokkaido/2/1981
Vaccine strain
H1N1
A/NC/20/99
Clinical isolate
H1N1
A/Osaka/16/2008
HI VN HI VN HI VN HI VN
2008JP, Lot. A 8 64 8 64 160 640 20 160
2008JP, Lot. B 8 64 8 64 160 640 20 160
2008JP, Lot. C 8 64 8 64 320 1280 40 160
1999US, Lot. D 16 64 16 64 40 128 16 32
1999JP, Lot. E 8 32 4 64 10 32 4 8
JP, Japan; US, United States; HI, haemagglutinin-inhibition; VN, virus neutralization.
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VKORC1 mutations in patients with partial resistance to
phenprocoumon
Coumarin derivatives, such as warfarin, phenprocoumon and
acenocoumarol, are used for long-term prevention of throm-
boembolic events. The management of oral anticoagulation
with coumarin derivatives is complicated by a large variability
in the dose-response relationship, which is partly determined
by genetic constitution (Rost et al, 2004; Bodin et al, 2005;
Sconce et al, 2005). Coumarins act by inhibiting the vitamin K
epoxide reductase (VKOR), encoded for by the VKORC1
(VKOR complex, subunit 1) gene. This enzyme recycles
vitamin K epoxide to the reduced form of vitamin K, an
essential cofactor in the formation of the active clotting factors
II, VII, IX, and X and the inhibitors protein C and S through
c-glutamyl carboxylation. While the most common VKORC1
genetic variants result in the need for lower doses of warfarin
during long-term therapy (Rieder et al, 2005; Sconce et al,
2005), some genetic variants confer coumarin resistance
(Bodin et al, 2005). International Normalized Ratio (INR)
values in combination with a plasma concentration of the
coumarin in use give a good indication of possible resistance
(Harrington et al, 2008). The known VKORC1 sequence
variants associated with coumarin resistance were recently
summarised (Peoc’h et al, 2009).
We report three patients presented with conﬁrmed (partial)
coumarin resistance. Patient 1 was initially treated with
acenocoumarol 12 mg/day, and subsequently with phenpro-
coumon, up to 9 mg/day. At this dose the phenprocoumon
serum concentration, determined by non-stereospeciﬁc
reversed phase high performance liquid chromatography and
diode array detector detection, was 4Æ3 mg/l (therapeutic range
1–3 mg/l). The INR did not rise above 1Æ4. Patient 2 was
treated with up to 9 mg phenprocoumon, which resulted in a
serum phenprocoumon concentration of 7Æ6 mg/l, while INRs
remained below 2Æ0. Patient 3 was initially treated with
acenocoumarol 8 mg/day, subsequently with phenprocoumon
9 mg/day. Serum phenprocoumon concentration was 6Æ6 mg/l,
while the INR was 1Æ3.
To investigate whether a genetic predisposition of coumarin
resistance was present in these three patients the VKORC1 5¢
UTR and coding sequence were analysed [AY587020 (Rieder
et al, 2005) annotates the wild type VKORC1 genomic
sequence]. Both Patients 1 and 3 were heterozygous for a
previously described nucleotide variation g.1310T>C (=
g.6621T>C in AY587020) in exon 2, leading to p.Trp59Arg
(Wilms et al, 2008). Patient 2 was heterozygous for a new
nucleotide variation, also a missense mutation g.155C>T in
exon 1 leading to p.Ser52Leu. None of the other previously
reported sequence variations associated with coumarin resis-
tance were detected in the three patients. In addition, no other
genetic alterations were found in the 5¢UTR (positions g.)226–
1 analysed), in exon 1 (positions g.1–173), in exon 2 (positions
g.1309–1418) and exon 3 (positions g.3388–3596). Both
Patients 1 and 2 were heterozygous for g.1173C>T, while
Patient 3 carried wild type. Individuals carrying g.1173T allele
in general require less phenprocoumon or acenocoumarol than
individuals carrying g.1173C alleles (Bodin et al, 2005; Rieder
et al, 2005; Sconce et al, 2005). Thus, the putative increased
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